Andere talen Hyloris Pharmaceuticals SA

Aandelen

HYL

BE0974363955

Farmaceutische producten

Beurs gesloten - Euronext Bruxelles Andere beurzen 15:46:31 14-04-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,340 ^EUR	+7,23%		+13,62%	-21,93%

29/03	Chemie voert Bel20 aan	AM
26/03	Kepler Cheuvreux ziet nog geen kantelpunt bij Hyloris	AM

Andere talen

31/03	Hyloris Pharmaceuticals : Regulated Information Information on the Total Number of Voting Rights and Shares (Denominator) FRENCH VERSION
26/03	Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones
26/03	Inside Information Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones FRENCH VERSION
26/03	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025
19/02	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION
19/02	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension FRENCH VERSION
19/02	Hyloris Pharmaceuticals : Provides Update on FDA Review of Valacyclovir for Oral Suspension
02/02	Hyloris Pharmaceuticals : Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings
02/02	Hyloris Pharmaceuticals : Regulated Information Information on the Total Number of Voting Rights and Shares (Denominator) FRENCH VERSION
20/01	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment
19/01	Hyloris Pharmaceuticals : Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets
19/01	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets ENGLISH VERSION
19/01	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets FRENCH VERSION
31/12	Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug
30/12	Hyloris Pharmaceuticals : Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed
30/12	Hyloris Pharmaceuticals obtains exclusive license rights in Europe & Turkey from Arbormed for its Wilson's disease therapy
30/12	Hyloris Pharmaceuticals : Inside Information Hyloris Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed ENGLISH VERSION
30/12	Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution
29/12	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSION
29/12	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. FRENCH VERSION
29/12	Hyloris announces partnership with Rosemont Pharmaceuticals for atomoxetine oral solution in the U.S.
12/12	Hyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder Therapy
11/12	Hyloris Pharmaceuticals : Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder
11/12	Hyloris Pharmaceuticals : Non-Regulated Information Hyloris Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder ENGLISH VERSION
11/12	Hyloris Pharmaceuticals : Non-Regulated Information Hyloris Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder FRENCH VERSION